Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective.

Abstract

PURPOSE:

Telotristat ethyl (TE) was recently approved for carcinoid syndrome diarrhea (CSD) in patients not adequately controlled with somatostatin analog long-acting release (SSA LAR) therapy alone. A budget impact model was developed to determine the short-term affordability of reimbursing TE in a US health plan.

METHODS:

A budget impact model compared health care costs when CSD is managed per current treatment patterns (SSA LAR, reference drug scenario) versus when TE is incorporated in the treatment algorithm (SSA LAR + TE, new drug scenario). Prevalence of CSD, proportion of patients not adequately controlled on SSA LAR, monthly treatment costs (pharmacy and medical), and treatment efficacy were derived from the literature. In the reference drug scenario, an escalated monthly dose of SSA LAR therapy of 40 mg was assumed to treat patients with CSD not adequately controlled on the labeled dose of SSA LAR. In the new drug scenario, TE was added to the maximum labeled monthly dose of SSA LAR therapy of 30 mg. The incremental budget impact was calculated based on an assumed TE market uptake of 28%, 42%, and 55% during Years 1, 2, and 3, respectively. One-way sensitivity analyses were conducted to test model assumptions.

FINDINGS:

A hypothetical health plan of 1 million members was estimated to have 42 prevalent CSD patients of whom 17 would be inadequately controlled on SSA LAR therapy. The monthly medical cost per patient not adequately controlled on SSA LAR in addition to pharmacotherapy was estimated to be $3946 based on the literature. Based on the observed treatment response in a clinical trial of 20% and 44% for the base case reference and new drug scenarios, total per patient per month costs were estimated to be $7563 and $11,205, respectively. Total annual costs in the new drug scenario were estimated to be $2.3 to $2.5 million during the first 3 years. The overall incremental annual costs were estimated to be $154,000 in Year 1, $231,000 in Year 2, and $302,000 in Year 3. This translated to an incremental per patient per month cost of $0.013, $0.019, and $0.025 for Years 1, 2, and 3. These results remained robust in 1-way sensitivity analyses.

IMPLICATIONS:

The availability of TE for patients not adequately controlled on SSA LAR therapy provides a novel treatment option for CSD. This model showed that providing access to this first-in-class oral agent would have a minimal budget impact to a US health plan.

• Authors: Vijay N Joish, Feride Frech, Pablo Lapuerta
• Journal: Clinical therapeutics (Clin Ther) Vol. 39 Issue 12 Pg. 2338-2344 (Dec 2017) ISSN: 1879-114X [Electronic] United States
• PMID: 29175096 (Publication Type: Journal Article)
• Copyright: Copyright © 2017 Elsevier HS Journals, Inc. All rights reserved.

Chemical References

• Antidiarrheals
• Pyrimidines
• Phenylalanine
• Somatostatin
• telotristat ethyl

Topics

• Antidiarrheals (economics, therapeutic use)
• Budgets
• Diarrhea (drug therapy, economics)
• Health Care Costs
• Humans
• Insurance, Health
• Malignant Carcinoid Syndrome (drug therapy, economics)
• Models, Economic
• Phenylalanine (analogs & derivatives, economics, therapeutic use)
• Pyrimidines (economics, therapeutic use)
• Somatostatin (analogs & derivatives, economics, therapeutic use)
• United States